CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
afegostat tartratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00446550
NCT00446550Phase 2Completed
CompareCT.gov

A Randomized, Open-label Study To Assess the Safety and Tolerability of AT2101 in Treatment-naive Adult Patients With Type 1 Gaucher Disease

Amicus Therapeutics·interventional·Posted Mar 13, 2007·Updated Aug 15, 2018

In Brief

A Phase 2 clinical trial evaluating afegostat tartrate for Gaucher Disease and 2 related conditions. Completed, enrolled 19 participants across 11 sites in 4 countries.

Detailed Summary

This study evaluated the safety and tolerability of afegostat tartrate in participants with type 1 Gaucher disease who were not receiving enzyme replacement therapy (ERT) or substrate reduction therapy (SRT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGaucher Disease, Type 1 Gaucher Disease, Gaucher Disease, Type 1
CountriesIsrael, South Africa, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 13, 2007
Enrollment StartJun 11, 2008
Primary CompletionAug 20, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.3 years ago

Interventions

afegostat tartratedrug